The core business segment focuses on the development, commercialization, and support of the Inspire system, a neurostimulation technology for treating obstructive sleep apnea (OSA). Research and development activities include continuous improvement of the existing system, exploring new applications, and enhancing patient outcomes. Technologies used include implantable medical devices, neurostimulation, and advanced surgical techniques. This segment addresses the needs of patients with moderate to severe OSA who have not benefited from CPAP therapy. Market positioning is strong due to the minimally invasive nature of the treatment and its effectiveness. Future opportunities include expanding into new markets, developing next-generation devices, and exploring new indications. Regulatory and clinical aspects are critical, with ongoing clinical trials and FDA approvals. Partnerships with sleep specialists, ENT surgeons, and hospitals are essential for market access and patient care. The Inspire V system is the latest innovation in this segment.